Allos AI

To add a bio or update company history, please click update information.

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

13 Jan 2026

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

Allos AI applies causal AI to reformulate complex generic drugs, improving delivery, tolerability and predictability while reducing development uncertainty.

Life Sciences
Oxford, United Kingdom
£4m
allos.ai
Update Information

More venture news

Perceptic
28 May 2026
Perceptic raises a £9m seed round led by Accel to unify drug discovery and development on a single AI platform
SeedLife Sciences
Imperagen
21 May 2026
Imperagen secures a £5m seed round led by PXN Ventures to accelerate the process of enzyme engineering
SeedLife Sciences
Infex Therapeutic
12 May 2026
Infex Therapeutics secures £4.3m in funding led by Jon Moulton for antimicrobial resistance treatments
EquityLife Sciences

Allos AI

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

More venture news

Perceptic raises a £9m seed round led by Accel to unify drug discovery and development on a single AI platform

Imperagen secures a £5m seed round led by PXN Ventures to accelerate the process of enzyme engineering

Infex Therapeutics secures £4.3m in funding led by Jon Moulton for antimicrobial resistance treatments